Liver transplant diabetes study tests which drug better fights fatty liver
NCT ID NCT05042505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 100 liver transplant patients with diabetes to see if dapagliflozin or sitagliptin is better at reducing liver fat and improving body composition. Participants took one of the two drugs for 12 months. The goal was to find a safer and more effective way to manage diabetes and prevent fatty liver after transplant, since these patients must take lifelong immunosuppressants that raise blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division Of Endocrinology & Diabetes, Medanta The Medicity
Gurgaon, Haryana, 122001, India